<DOC>
	<DOCNO>NCT02955251</DOCNO>
	<brief_summary>This open-label , Phase I , dose-escalation study determine recommend Phase 2 dose ( RPTD ) , maximum tolerate dose ( MTD ) , evaluate safety pharmacokinetic ( PK ) profile ABBV-428 administer monotherapy combination nivolumab participant advance solid tumor .</brief_summary>
	<brief_title>A Study Evaluating Safety Pharmacokinetics , Recommended Phase 2 Dose ( RPTD ) ABBV-428 Participants With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Participants must advance solid tumor progress standard therapy know provide clinical benefit participant intolerant therapy . Participants adequate bone marrow , renal , hepatic coagulation function . For dose expansion arm , participant must measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) Version 1.1 Participants combination therapy cohorts must advance solid tumor use nivolumab standard therapy . Active prior document autoimmune disease last 2 year . Participants childhood atopy asthma , vitiligo , alopecia , Hashimoto syndrome , Grave 's disease , psoriasis require systemic treatment ( within past 2 year ) exclude . Current prior use immunosuppressive medication within 14 day prior first dose ( certain exception ) . History primary immunodeficiency , bone marrow transplantation , chronic lymphocytic leukemia , solid organ transplantation , previous clinical diagnosis tuberculosis . Confirmed positive test result human immunodeficiency virus ( HIV ) , participant chronic active hepatitis B C. Participants history hepatitis B C document cure antiviral therapy may enrol . Prior grade great equal 3 immunemediated neurotoxicity pneumonitis ( unresolved symptomatic adverse event last 3 month ) receive immunotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Non-squamous NSCLC</keyword>
	<keyword>Advanced solid tumor</keyword>
	<keyword>Ovarian cancer</keyword>
	<keyword>Non-small cell lung cancer ( NSCLC )</keyword>
	<keyword>Cancer</keyword>
	<keyword>Neoplasm</keyword>
	<keyword>Nivolumab</keyword>
</DOC>